In the central nervous system, basal ganglia structures are highly susceptible to infection with the human immunodeficiency virus-1 (HIV). The HIV-1 protein, Tat, which is involved in viral replication, also plays an important role in the neuronal injury and recapitulates much the pathology seen in HIV-1 infection of the brain. Patients with HIV-1 infection often abuse drugs such as methamphetamine, a drug that is well known to also cause long-term structural and functional changes of the basal ganglia. Previous studies from our laboratory have demonstrated that Tat protein and methamphetamine interacted synergistically to cause profound damage to the basal ganglia dopaminergic neurotransmitter system. Although our earlier studies implicated reactive oxygen species and the cytokine TNF-1, our preliminary data strongly suggest that ceramide-induced alterations of the vesicular monoamine transporter may play a prominent role in the enhanced toxicity of MA seen after exposure to Tat. In this proposal, we will in Specific Aim 1, determine whether HIV-1 Tat alters the compartmentalization of DA in the synaptic terminal.
In Specific Aim 2, we will investigate whether the production of the second messenger ceramide is involved in Tat-induced changes in dopamine compartmentalization. Lastly, in Specific Aim 3, we will determine whether ceramide mediates the synergism between Tat and methamphetamine. Both pharmacological and genetic inhibition of ceramide synthesis will be pursued. In studying these interactions, we will examine 1) vesicular mononamine transporter function, 2) dopamine release (vesicular and tissue) 3) dopamine terminal integrity and 4) behavioral measures. The results of these experiments will elucidate a novel role for ceramide signaling in dopaminergic dysfunction, not only in HIV-1, but also in the neuronal injury associated with Parkinson's disease.

Public Health Relevance

In 2009, there were more than 24,000 HIV-1 Infected Veterans in VHA care. HIV-1 infection often affects the brain and results in a condition known as HIV Associated Dementia (HAD), which include symptoms such as involuntary muscle activity, abnormal cognition and behavioral abnormalities. Among Veterans who are HIV-1 positive, approximately 30% use illicit drugs and methamphetamine, perhaps due to its enhancement of sexual behavior, is frequently the drug of choice in this population. Recent neuropathological studies have revealed that HIV-1 patients who abuse methamphetamine are vulnerable to a more severe form of nervous system damage by HIV-1. In this project, we will examine how the important HIV protein, Tat, to which exposure mimics HIV-! pathology, interacts with methamphetamine to cause enhanced brain injury. Progress in this research will open up a new avenue for mechanistically-based, therapeutic intervention for HIV-1 infected, methamphetamine abusing patients.

National Institute of Health (NIH)
Veterans Affairs (VA)
Non-HHS Research Projects (I01)
Project #
Application #
Study Section
Neurobiology A (NURA)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
VA Veterans Administration Hospital
United States
Zip Code
Schier, Christina J; Marks, William D; Paris, Jason J et al. (2017) Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice. J Neurosci 37:5758-5769
Theodore, Shaji; Cass, Wayne A; Dwoskin, Linda P et al. (2012) HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse 66:755-7